RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study
TOKYO–(BUSINESS WIRE)–RIBOMIC Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, today announced that...